【摘要】 目的探讨左西孟旦治疗慢性心力衰竭患者的效果。方法选取2013年1—12月于山东大学齐鲁医院心内科住院的77例患者,随机分为试验组(40例)和对照组(37例)。对照组给予常规治疗,试验组在对照组基础上加用左西孟旦治疗,比较两组临床有效率及治疗前后的血清氨基末端脑利钠肽前体(NT-proBNP)和肽素(Copeptin)水平变化情况。结果试验组临床有效率为89.2%,对照组为62.5%,差异有统计学意义(P<0.05)。治疗72 h后,试验组与对照组的Copeptin分别下降了(634.49±485.01)pg/ml和(328.78±261.25)pg/ml(P<0.05),NT-proBNP分别下降了(2 097.85±840.68)pg/ml和(1 375.77±879.07)pg/ml(P<0.05),试验组2个指标下降幅度均大于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论左西孟旦可明显降低慢性心力衰竭患者的血清Copeptin和NT-ProBNP水平,缓解患者的症状和体征。更多还原

【Abstract】 Objective To investigate the effect of levosimendan on patients with chronic heart failure.Methods From January to December 2013, 77 patients hospitalized in the Department of Cardiology, Qilu Hospital of Shandong University were randomly divided into experimental group(40 cases) and control group(37 cases).The control group were treated with conventional treatment, and the experimental group were treated with levosimendan on the basis of conventional treatment.The serum Copeptin concentration and ammonia N-terminal brain natriuretic peptide precursor(NT-proBNP) levels before and 72 hours after treatment of two groups were compared, and the overall clinical status were observed.Results The overall clinical status rate was 89.2% in the experimental group and 62.5% in the control group, the difference was statistically significant(P<0.05).After treatment, the blood Copeptin levels in the experimental group and the control group decreased by(634.49±485.01) pg/ml and(328.78±261.25) pg/ml, respectively(P<0.05).After treatment, NT-proBNP decreased by(2 097.85±840.68) pg/ml and(1 375.77±879.07) pg/ml, respectively(P<0.05).There was no significant difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion Levosimendan can reduce the serum levels of Copeptin and NT-proBNP in patients with chronic heart failure, relieve the symptoms and signs of patients.更多还原